Cargando…

COVID-19 and Myocarditis: What Do We Know So Far?

COVID-19 has been declared a global pandemic by the World Health Organization and is responsible for hundreds of thousands of deaths worldwide. COVID-19 is caused by SARS-CoV-2, and common clinical symptoms include fever, cough, sore throat, headache, and fatigue. Myocardial injury is relatively com...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirzada, Ashar, Mokhtar, Ahmed T., Moeller, Andrew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254016/
https://www.ncbi.nlm.nih.gov/pubmed/32691024
http://dx.doi.org/10.1016/j.cjco.2020.05.005
_version_ 1783539446284550144
author Pirzada, Ashar
Mokhtar, Ahmed T.
Moeller, Andrew D.
author_facet Pirzada, Ashar
Mokhtar, Ahmed T.
Moeller, Andrew D.
author_sort Pirzada, Ashar
collection PubMed
description COVID-19 has been declared a global pandemic by the World Health Organization and is responsible for hundreds of thousands of deaths worldwide. COVID-19 is caused by SARS-CoV-2, and common clinical symptoms include fever, cough, sore throat, headache, and fatigue. Myocardial injury is relatively common in patients with COVID-19, accounting for 7%-23% of cases, and is associated with a higher rate of morbidity and mortality. There is a discrepancy in the literature about myocarditis as the etiology of myocardial injury in patients with COVID-19; although many anecdotal reports of myocarditis have been noted, there are only a handful of case reports in the literature about myocarditis related to COVID-19. In this review we summarize the most up to date literature around the association between COVID-19 and myocarditis and provide clinicians a practical framework about the clinical manifestations, diagnostic tools, and treatment options currently available. Importantly, this review will heighten suspicion for myocarditis as an etiology of myocardial injury in COVID-19 patients, therefore improving clinical outcomes and encouraging shared clinical decision-making. This will also open the door for further research to build around this review. Emergent treatment options for COVID-19 are in clinical trials and might be of benefit to COVID-19 patients with myocarditis in addition to current guideline-based recommendations.
format Online
Article
Text
id pubmed-7254016
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72540162020-05-28 COVID-19 and Myocarditis: What Do We Know So Far? Pirzada, Ashar Mokhtar, Ahmed T. Moeller, Andrew D. CJC Open Review COVID-19 has been declared a global pandemic by the World Health Organization and is responsible for hundreds of thousands of deaths worldwide. COVID-19 is caused by SARS-CoV-2, and common clinical symptoms include fever, cough, sore throat, headache, and fatigue. Myocardial injury is relatively common in patients with COVID-19, accounting for 7%-23% of cases, and is associated with a higher rate of morbidity and mortality. There is a discrepancy in the literature about myocarditis as the etiology of myocardial injury in patients with COVID-19; although many anecdotal reports of myocarditis have been noted, there are only a handful of case reports in the literature about myocarditis related to COVID-19. In this review we summarize the most up to date literature around the association between COVID-19 and myocarditis and provide clinicians a practical framework about the clinical manifestations, diagnostic tools, and treatment options currently available. Importantly, this review will heighten suspicion for myocarditis as an etiology of myocardial injury in COVID-19 patients, therefore improving clinical outcomes and encouraging shared clinical decision-making. This will also open the door for further research to build around this review. Emergent treatment options for COVID-19 are in clinical trials and might be of benefit to COVID-19 patients with myocarditis in addition to current guideline-based recommendations. Elsevier 2020-05-28 /pmc/articles/PMC7254016/ /pubmed/32691024 http://dx.doi.org/10.1016/j.cjco.2020.05.005 Text en © 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Pirzada, Ashar
Mokhtar, Ahmed T.
Moeller, Andrew D.
COVID-19 and Myocarditis: What Do We Know So Far?
title COVID-19 and Myocarditis: What Do We Know So Far?
title_full COVID-19 and Myocarditis: What Do We Know So Far?
title_fullStr COVID-19 and Myocarditis: What Do We Know So Far?
title_full_unstemmed COVID-19 and Myocarditis: What Do We Know So Far?
title_short COVID-19 and Myocarditis: What Do We Know So Far?
title_sort covid-19 and myocarditis: what do we know so far?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254016/
https://www.ncbi.nlm.nih.gov/pubmed/32691024
http://dx.doi.org/10.1016/j.cjco.2020.05.005
work_keys_str_mv AT pirzadaashar covid19andmyocarditiswhatdoweknowsofar
AT mokhtarahmedt covid19andmyocarditiswhatdoweknowsofar
AT moellerandrewd covid19andmyocarditiswhatdoweknowsofar